Elevance (ELV) Medicaid margin recovery pushed out to 2027-28 - Mizuho

July 17, 2025 11:39 AM

Mizuho analyst Ann Hynes reiterated an Outperform rating and $505.00 price target on Elevance (NYSE: ELV) following cautious commentary on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found